Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Theobald, 2015, [Immunological tumor therapy], Der Internist, 56, 907
Zang, 2015, New immunotherapies targeting the PD-1 pathway, Trends in pharmacological sciences, 36, 587, 10.1016/j.tips.2015.06.005
Kreamer, 2014, Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer, Journal of the advanced practitioner in oncology, 5, 418
Chen, 2008, Inhibitory B7-family molecules in the tumour microenvironment, Nature reviews Immunology, 8, 467, 10.1038/nri2326
Yagita, 2002, Expression of Programmed Death 1 Ligands by Murine T Cells and APC, The Journal of Immunology, 169, 5538, 10.4049/jimmunol.169.10.5538
Honjo, 2002, Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues, Immunology letters, 84, 57, 10.1016/S0165-2478(02)00142-6
Pardoll, 2012, Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity, Current opinion in immunology, 24, 207, 10.1016/j.coi.2011.12.009
Zhang, 2015, The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients, Oncotarget, 6, 19393, 10.18632/oncotarget.5107
Kelly, 2015, Immunotherapy in upper GI malignancies, Current treatment options in oncology, 16, 20, 10.1007/s11864-015-0336-6
Khleif, 2015, Programmed death-1 & its ligands: promising targets for cancer immunotherapy, Immunotherapy, 7, 777, 10.2217/imt.15.49
Abdollahi, 2015, Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma, Expert Review of Anticancer Therapy, 15, 981, 10.1586/14737140.2015.1074862
Odunsi, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, New England Journal of Medicine, 366, 2455, 10.1056/NEJMoa1200694
Atkins, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, New England Journal of Medicine, 366, 2443, 10.1056/NEJMoa1200690
Nakamura, 2015, Nivolumab in the treatment of malignant melanoma: review of the literature, OncoTargets and therapy, 8, 2045, 10.2147/OTT.S62102
Felip, 2015, Pembrolizumab for the treatment of non-small-cell lung cancer, The New England journal of medicine, 372, 2018, 10.1056/NEJMoa1501824
Ribas, 2015, Anti-programmed cell death protein-1/ligand-1 therapy in different cancers, British journal of cancer, 112, 1421, 10.1038/bjc.2015.124
Wang, 2014, Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial, The Lancet Oncology, 15, 69, 10.1016/S1470-2045(13)70551-5
Lawrence, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011
Arrieta, 2015, Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer, The New England journal of medicine, 373, 1627, 10.1056/NEJMoa1507643
Gainor, 2015, Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, The New England journal of medicine, 373, 123, 10.1056/NEJMoa1504627
Wagstaff, 2015, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England journal of medicine, 373, 23, 10.1056/NEJMoa1504030
He, 2016, Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial, The Lancet Oncology, 387, 1837
Gurney, 2015, Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma, The New England journal of medicine, 373, 1803, 10.1056/NEJMoa1510665
Minor, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, The New England journal of medicine, 372, 2006, 10.1056/NEJMoa1414428
O’Day, 2015, Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial, The Lancet Oncology, 16, 908, 10.1016/S1470-2045(15)00083-2
Lebbe, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, The New England journal of medicine, 372, 320, 10.1056/NEJMoa1412082
Neyns, 2015, Pembrolizumab versus Ipilimumab in Advanced Melanoma, The New England journal of medicine, 372, 2521, 10.1056/NEJMoa1503093
Lorigan, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, 16, 375, 10.1016/S1470-2045(15)70076-8
Wolchok, 2015, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, The New England journal of medicine, 373, 1270, 10.1056/NEJMc1509660
Burns, 2015, Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma, Experimental hematology & oncology, 4, 34, 10.1186/s40164-015-0029-7
Anders, 2014, Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy, Clinical cancer research, 20, 5064, 10.1158/1078-0432.CCR-13-3271
Rocken, 2016, Immunotherapy of melanoma: efficacy and mode of action, Journal of the German Society of Dermatology: JDDG, 14, 28
Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nature reviews Cancer, 12, 252, 10.1038/nrc3239
Amin, 2015, Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities, Translational lung cancer research, 4, 560
Altman, 2003, Measuring inconsistency in meta-analyses, BMJ: British Medical Journal, 327, 557, 10.1136/bmj.327.7414.557